Intake of 5-ARIs for BPH not associated with increased mortality in prostate cancer
Researchers have found in a new study that Intake of 5-ARIs for BPH is not associated with increased mortality in prostate cancer. The study has been published in the journal of American Medical Association.
"Our results indicate that 5-ARIs are safe to use regarding the risk of prostate cancer, and we hope that this study will alleviate concerns and allow for better access to these drugs for men suffering from lower urinary symptoms caused by benign prostate hyperplasia", says Lars Björnebo, first author of the study and PhD Candidate at the Department of Medical Biostatistics and Epidemiology.
A previous study from the same research group published in 2018 found a decrease in diagnosed prostate cancer for men treated with 5-ARI. "We wanted to assess whether our previous results had an implication for mortality in prostate cancer, says Anna Lantz, senior author and Associate Professor at Karolinska Institutet.
Two large randomized controlled trials, PCPT and REDUCE, performed to assess whether 5-ARIs could be used to prevent prostate cancer found an overall lower risk of prostate cancer in men treated with the drug. However, both trials also found an increased rate of more aggressive forms of prostate cancer.
These findings were later attributed to increased sensitivity of PSA and biopsies for men treated with the drugs. Nevertheless, it subsequently led to a hesitancy to prescribe the medications and a warning from the US Food and Drug Administration, which was later withdrawn.Since then, many observational studies have been published with varying results concerning the risk of developing and dying from prostate cancer in men treated with 5-ARIs. The long-term follow-up of the randomized trials has not shown any increased risk of dying from prostate cancer in men treated with 5-ARIs.
This large population-based cohort study included 349 152 men, with 26 190 men receiving Finasteride or Dutasteride during the study period between 2007 and 2018. By linking multiple Swedish registries, the researchers were able to adjust for numerous confounders and ensure that the included men were free from prostate cancer and 5-ARI treatment at the start of the study. "This is the first observational study considering 5-ARIs and prostate cancer mortality in men without a previous diagnosis of prostate cancer, which is essential for studying this association", says Lars Björnebo.
The study saw no increased risk of dying from prostate cancer for men treated with 5-ARIs, but a decreased risk after longer treatment durations. A higher frequency of testing for prostate cancer with both PSA and biopsies was also observed in the men treated with 5-ARIs.
"We cannot say definitively whether the drug, increased testing or something else is causing the decrease in prostate cancer mortality," says Lars Björnebo. "We do not believe further clinical trials with these drugs are beneficial. Our main message is that these drugs are safe to use as intended."
